Characterization of bropirimine O-glucuronidation in human liver microsomes

Xenobiotica

Volumn 33, Issue 10, 2003, Pages 999-1011

  Wynalda, M A ^a   Wynalda, K M ^a   Amore, B M ^a   Fagerness, P E ^a   Wienkers, L C ^a  

^a Drug Metabolism Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCURONIDASE; BILIRUBIN; BROPIRIMINE; BROPIRIMINE O GLUCURONIDE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A9; MEFENAMIC ACID; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG GLUCURONIDATION; DRUG INHIBITION; DRUG SENSITIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME KINETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; KIDNEY MICROSOME; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; LIVER MICROSOME METABOLISM; MASS SPECTROMETRY; MICHAELIS MENTEN KINETICS; PROTON NUCLEAR MAGNETIC RESONANCE; RADIOCHEMISTRY;

ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; CYTOSINE; ENZYME INHIBITORS; GLUCURONIDASE; GLUCURONOSYLTRANSFERASE; HUMANS; KIDNEY; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MICROSOMES; MICROSOMES, LIVER; MODELS, CHEMICAL; RECOMBINANT PROTEINS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TIME FACTORS;

EID: 0242288639     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250310001602757     Document Type: Article

References (38)

1. BERTZ, R. J. and GRANNEMAN, G. R., 1997, Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clinical Pharmacokinetics, 32, 210-258.
2. BOERSMA, M. G., VAN DER WOUDE, H., BOGAARDS, J., BOEREN, S., VERVOORT, J., CNUBBEN, N. H., VAN IERSEL, M. L., VAN BLADEREN, P. J. and RIETJENS, I. M., 2002, Regioselectivity of Phase II metabolism of luteolin and quercetin by UDP-glucuronosyl transferases. Chemical Research in Toxicology, 15, 662-670.
3. BURCHELL, B., NEBERT, D. W., NELSON, D. R., BOCK, K. W., IYANAGI, T., JANSEN, P. L., LANCET, D., MULDER, G. J., CHOWDHURY, J. R. and SIEST, G., 1991, The UDP glucuronosyltransferase gene superfamily: suggested nomenclature based on evolutionary divergence. DNA Cell Biology, 10, 487-494.
4. CIOTTI, M., MARRONE, A., POTTER, C. and OWENS, I. S., 1997, Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: pharmacological implications. Pharmacogenetics, 7, 485-495.
5. COURT, M. H., DUAN, S. X., VON MOLTKE, L. L., GREENBLATT, D. J., PATTEN, C. J., MINERS, J. O. and MACKENZIE, P. I., 2001, Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. Journal of Pharmacology and Experimental Therapeutics, 299, 998-1006.
6. EBNER, T. and BURCHELL, B., 1993, Substrate specificities of two stably expressed human liver UDP-glucuronosyltransferases of the UGT1 gene family. Drug Metabolism and Disposition, 21, 50-55.
7. EBNER, T., REMMEL, R. P. and BURCHELL, B., 1993, Human bilirubin UDP-glucuronosyltransferase catalyses the glucuronidation of ethinylestradiol. Molecular Pharmacology, 43, 649-654.
8. ETHELL, B. T., EKINS, S., WANG, J. and BURCHELL, B., 2002, Quantitative structure activity relationships for the glucuronidation of simple phenols by expressed human UGT1A6 and UGT1A9. Drug Metabolism and Disposition, 30, 734-738.
9. FISHER, M. B., VANDENBRANDEN, M., FINDLAY, K., BURCHELL, B., THUMMEL, K. E., HALL, S. D., WRICHTON, S. A., 2000, Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank. Pharmacogenetics, 10, 727-739.
10. GAGNE, J. F., MONTMINY, V., BELANGER, P., JOURNAULT, K., GAUCHER, G. and GUILLEMETTE, C., 2002, Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Molecular Pharmacology, 62, 608-617.
11. GREEN, M. D., BISHOP, W. P. and TEPHLY, T. R., 1995, Expressed human UGT1. 4 protein catalyses the formation of quaternary ammonium-linked glucuronides. Drug Metabolism and Disposition, 23, 299-302.
12. GREEN, M. D., KING, C. D., MOJARRABI, B., MACKENZIE, P. I. and TEPHLY, T. R., 1998, Glucuronidation of amines and other xenobiotics catalysed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metabolism and Disposition, 26, 507-512.
13. HAGENAUER, B., SALAMON, A., THALHAMMER, T., KUNERT, O., HASLINGER, E., KLINGLER, P., SENDEROWICZ, A. M., SAUSVILLE, E. A. and JAGER, W., 2001, In vitro glucuronidation of the cyclin-dependent kinase inhibitor flavopiridol by rat and human liver microsomes: involvement of UDP-glucuronosyltransferases 1A1 and 1A9. Drug Metabolism and Disposition, 29, 407-414.
14. HALPIN, R. A., PORRAS, A. G., GEER, L. A., DAVIS, M. R., CUI, D., DOSS, G. A., WOOLF, E., MUSSON, D., MATTHEWS, C., MAZENKO, R., SCHWARTZ, J. I., LASSETER, K. C., VYAS, K. P. and BAILLIE, T. A., 2002, The disposition and metabolism of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in human subjects. Drug Metabolism and Disposition, 30, 684-693.
15. 14C]bropirimine to healthy human volunteers. Proceedings of the 8th North American ISSX Meeting, Hilton Head, SC, Abstract 219, October 1997.
16. IYER, L., MORTELL, M. A., YAMAMOTO, Y., AZUMA, R. and RATAIN, M. J., 1998, Glucuronidation of TAS-103 by uridine diphosphate glucuronosyltransferase (UGT) isoforms 1A1 and 2: possible implication of TAS-103 toxicity in Gilbert's syndrome (Abstract). Annals of Oncology, 9, 61.
17. KADAKOL, A., GHOSH, S. S., SAPPAL, B. S., SHARMA, G., CHOWDHURY, J. R. and CHOWDHURY, N. R., 2000, Genetic lesions of bilirubin uridine- diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype. Human Mutation, 16, 297-306.
18. KEMP, D. C., FAN, P. W. and STEVENS, J. C., 2002, Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Drug Metabolism and Disposition, 30, 694-700.
19. KING, C. D., GREEN, M. D., RIOS, G. R., COFFMAN, B. L., OWENS, I. S., BISHOP, W. P. and TEPHLY, T. R., 1996, The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP- glucuronosyltransferase 1.1. Archives of Biochemistry and Biophysics, 332, 92-100.
20. LÉVESQUE, É., BEAULIEU, M., HUM, D. W. and BÉLANGER, A., 1999, Characterization and substrate specificity of UGT2B4 (E458): a UDP-glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics, 9, 207-216.
21. LUUKKANEN, L., MIKKOLA, J., FORSMAN, T., TAAVITSAINEN, P., TASKINEN, J. and ELOVAARA, E., 2001, Glucuronidation of 1-hydroxypyrene by human liver microsomes and human UDP-glucuronosyltransferases UGT1A6, UGT1A7, and UGT1A9: development of a high-sensitivity glucuronidation assay for human tissue. Drug Metabolism and Disposition, 29, 1096-1101.
22. MACKENZIE, P. I., OWENS, I. S., BURCHELL, B., BOCK, K. W., BAIROCH, A., BELANGER, A., FOURNEL-GIGLEUX, S., GREEN, M., HUM, D. W., IYANAGI, T., LANCET, D., LOUISOT, P., MAGOALOU, J., CHOWDHURY, J. R., RITTER, J. K., SCHACHTER, H., TEPHLY, T. R., TIPTON, K. F. and NEBERT, D. W., 1997, The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics, 7, 255-269.
23. MCGURK, K. A., BRIERLEY, C. H. and BURCHELL, B., 1998, Drug glucuronidation by human renal UDP-glucuronosyltransferases. Biochemical Pharmacology, 55, 1005-1012.
24. MCGURK, K. A., REMMEL, R. P., HOSAGRAHARA, V. P., TOSH, D. and BURCHELL, B., 1996, Reactivity of mefenamic acid 1-O-acyl glucuronide with proteins in vitro and ex vivo. Drug Metabolism and Disposition, 24, 842-849.
25. NAKAJIMA, M., TANAKA, E., KOBAYASHI, T., OHASHI, N., KUME, T. and YOKOI, T., 2002, Imipramine N-glucuronidation in human liver microsomes: biphasic kinetics and characterization of UDP-glucuronosyltransferase isoforms. Drug Metabolism and Disposition, 30, 636-642.
26. OWENS, I. S. and RITTER, J. K., 1995, Gene structure at the human UGT1 locus creates diversity in isozyme structure, substrate specificity, and regulation. Progress in Nucleic Acids Research and Molecular Biology, 51, 305-338.
27. RITTER, J. K., 2000, Roles of glucuronidation and UDP- glucuronosyltransferases in xenobiotic bioactivation reactions. Chemico-Biological Interactions, 129, 171-193.
28. SAROSDY, M. E., LAMM, D. L., WILLIAMS, R. D., MOON, T. D., FLANIGAN, R. C., CRAWFORD, E. D., WILKS, N. E., EARHART, R. H. and MERRITT, J. A., 1992, Phase 1 trail of oral bropirimine in superficial bladder cancer. Journal of Urology, 147, 31-34.
29. SEPPEN, J., BOSMA, P. J., GOLDHOORN, B. G., BAKKER, C. T., CHOWDHURY, J. R., CHOWDHURY, N. R., JANSEN, P. L. and OUDE ELFERINK, R. P., 1994, Discrimination between Crigler-Najjar type I and II by expression of mutant bilirubin uridine diphosphate-glucuronosyltransferase. Journal of Clinical Investigation, 94, 2385-2391.
30. SORICH, M. J., SMITH, P. A., MCKINNON, R. A. and MINERS, J. O., 2002, Pharmacophore and quantitative structure activity relationship modelling of UDP-glucuronosyltransferase 1A1 (UGT1A1) substrates. Pharmacogenetics, 12, 635-645.
31. TAKENAGA, N., ISHII, M., KAMEI, T. and YASUMORI, T., 2002, Structure-activity relationship in O-glucuronidation of indolocarbazole analogs. Drug Metabolism and Disposition, 30, 494-497.
32. TEPHLY, T. R. and BURCHELL, B., 1990, UDP-glucuronosyltransferases: a family of detoxifying enzymes. Trends in Pharmacological Science, 11, 276-279.
33. THRASHER, J. B. and CRAWFORD, E. D., 1993, Current management of invasive and metastatic cell carcinoma of the bladder. Journal of Urology, 149, 957-972.
34. TUKEY, R. H. and STRASSBURG, C. P., 2000, Human UDP- glucuronosyltransferases: metabolism, expression, and disease. Annual Reviews in Pharmacology and Toxicology, 40, 581-616.
35. WIENKERS, L. C., STEENWYK, R. C., SANDERS, P. E. and PEARSON, P. G., 1996, Biotransformation of tirilazad in human: 1. Cytochrome P450 3A-mediated hydroxylation of tirilazad mesylate in human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 277, 982-990.
36. WYNALDA, M. A., HAUER, M. J. and WIENKERS, L. C., 1998, Human biotransformation of bropirimine. characterization of the major bropirimine oxidative metabolites formed in vitro. Drug Metabolism and Disposition, 26, 1048-1051.
37. ZHENG, Z., FANG, J. L. and LAZARUS, P., 2002, Glucuronidation: an important mechanism for detoxification of benzo[a]pyrene metabolites in aerodigestive tract tissues. Drug Metabolism and Disposition, 30, 397-403.
38. ZHOU, H. H., SHELLER, J. R., NU, H., WOOD, M. and WOOD, A. J., 1993, Ethnic differences in response to morphine. Clinical and Pharmacological Therapy, 54, 507-513.